CEI Van Outreach Screening Study
This trial is active, not recruiting.
|Conditions||glaucoma, macular disease, keratoconus|
|Treatment||oct imaging, the fda cleared ivue|
|Sponsor||Oregon Health and Science University|
|Collaborator||National Eye Institute (NEI)|
|Start date||January 2012|
|End date||January 2014|
|Trial size||200 participants|
|Trial identifier||NCT01510392, OHSU IRB#00008034-Outreach|
The primary goal of the trial is to show that optical coherence tomography (OCT) technology can be used to effectively screen for diseases of the eye including glaucoma, macular diseases and keratoconus. Glaucoma is a disease that causes permanent vision loss and is usually accompanied by increased eye pressure. Macular diseases affect sharp, central vision. Keratoconus is a disease that affects the cornea (clear surface covering the colored part of the eye).
OCT screening efficacy for detection of early stage eye diseases in comparison to the current standard of care methods
time frame: 1 year
Male or female participants from 18 years up to 89 years old.
Inclusion Criteria: - Participant undergoing a screening examination at the Casey Eye Institute Outreach Van. - Participants must be between the ages of 18 and 89 years old. Exclusion Criteria: - Inability to give informed consent. - Inability to maintain stable fixation for OCT imaging
|Official title||Prospective Evaluation of Optical Coherence Tomography Usage in the Screening of Eye Diseases|
|Principal investigator||Michael Chiang, MD|
|Description||The identification of many eye diseases would significantly benefit from earlier detection than is available with typical eye exams. Optical coherence tomography (OCT) is an imaging technology that can perform non-contact cross-sectional imaging of tissue structure in real time. It is similar to ultrasound B-mode imaging, except that OCT measures the intensity of reflected light rather than sound waves.|
Call for more information